Outset Medical Inc expected to post a loss of 42 cents a share - Earnings Preview

Outset Medical

03/01/2025 13:33

* Outset Medical Inc  OM.OQ   OM.O  is expected to show a
fall in
quarterly revenue when it reports  results on January 6
(estimated) for the period ending December 31 2024
    * The San Jose California-based  company is expected to
report a
8.7% decrease in revenue to $27.854 million from $30.51 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Outset Medical Inc is
for a
loss of 42 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Outset
Medical
Inc is $3.50​, above​ its last closing price of $1.17. ​​​

The company's guidance on August 7 2024 for the period ended
December 31 was for gross profit margin between 34% and 36%.
Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.42       -0.42      -0.39     Beat    7.5
 Jun. 30 2024  -0.45       -0.45      -0.47     Missed  -4.1
 Mar. 31 2024  -0.56       -0.55      -0.57     Missed  -3.9​
 Dec. 31 2023  -0.61       -0.61      -0.59     Beat    4.1
 ​​Sep.        -0.67       -0.67      -0.71     Missed  -6.5
 30 2023                                                
 Jun. 30 2023  -0.84       -0.76      -0.90     Missed  -18​
 Mar. 31 2023  -0.78       -0.74      -0.90     Missed  -21.3
 Dec. 31 2022  -0.91       -0.86      -0.86     Met     0
 This summary was machine generated January 3 at 13:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)